Faculty Profile

Dr. Mimi Kim, Sc.D.

Mimi Kim, Sc.D.

Professor, Department of Epidemiology & Population Health

Harold and Muriel Block Chair in Epidemiology & Population Health

Division Head, Division of Biostatistics, Department of Epidemiology & Population Health

Director, Biostatistics, Epidemiology and Research Design Core of the Institute for Clinical and Translational Research

Director, Quantitative Sciences in Biomedical Research Center

Areas of Research: Clinical trials; misclassification and measurement error; survival analysis, cancer, rheumatology, infectious diseases

Professional Interests

Dr. Kim’s research focuses on statistical methods for designing and analyzing clinical trials and epidemiologic studies (research of the factors affecting health and illness).  Most clinical trials aim to demonstrate superiority of an experimental treatment relative to a standard treatment or placebo.  An increasing number of trials, however, seek to show that the effects of two treatments on a particular outcome are equivalent, or that one treatment is not inferior to another. These goals are of interest when the new therapy offers benefits such as reduced cost, toxicity, or invasiveness. Dr. Kim is investigating the effects of non-compliance, outcome misclassification and measurement error on equivalence and non-inferiority trials and developing new approaches for defining the non-inferiority margin. Her research interests also include the development of methods for analyzing multivariate and interval-censored survival data. In addition, she collaborates on studies in cancer, rheumatology, and HIV/AIDS.

Dr. Kim has been head of  the Division of Biostatistics since 2003, is Director of the Biostatistics Shared Resource of the Institute of Clinical and Translational Research,and Director of the Center for Quantitative Sciences. She is a Fellow of the American Statistical Association, on the Board of Trustees of the National Institute of Statistical Sciences, was Vice Chair of the American Statistical Association Council of Chapters Governing Board, President of the Korean International Statistical Society, and on the Medical and Scientific Advisory Council of the Lupus Foundation of America. She has participated on numerous grant review panels for the National Institutes of Health and was a member of the NIH Arthritis, Musculoskeletal and Skin Diseases Clinical Trials Review Committee.

Selected Publications

Kim, M.Y. and Goldberg, J.D.  The effects of outcome misclassification and measurement error on the design and analysis of therapeutic equivalence trials. Statistics in Medicine 2001; 2065-2078.
 
Kim, M.Y. and Xue, X.  The analysis of multivariate interval-censored survival data. Statistics in Medicine 2002; 21: 3715 – 3726.
 
Kim, M.Y. and Xue, X. Likelihood ratio and a Bayesian approach were superior to standard noninferiority analysis when the noninferiority margin varied with the control event rate.   Journal of Clinical Epidemiology 2004; 57: 1253-1261. 
 

Petri, M., Kim, M., Kalunian, K., et al.  Combined oral contraceptives are not associated with an increased rate of flare in SLE patients in the SELENA Trial. New England Journal of Medicine 2005; 353:2550 - 2558.

Ginzler, E., Dooley, M., Aranow, C., Kim, M., et al. Comparison of mycophenolate mofetil to intravenous cyclophosphamide for induction therapy of severe active lupus nephritis.   New England Journal of Medicine 2005; 353: 2219 - 2228.

Buyon, J., Petri, M., Kim, M., et al. . Estrogen/Cyclic progesterone replacement is associated with an increased rate of mild/moderate but not severe flares in SLE: The SELENA Trial.  Annals of Internal Medicine 2005; 953 - 962.

Sheng, D. and Kim, M.Y. The effects of non-compliance on intent-to-treat analysis of equivalence trials. Statistics in Medicine 2006; 25:1183-1199.

Kim, M.Y., Xue, X., Du, E.  Approaches for calculating power for case-cohort studies.  Biometrics 2006; 62: 929-922.

Xue, X., Kim, M., and Shore, R.  Cox regression analysis in presence of collinearity: an application to assessment of health risks associated with occupational radiation exposure. Lifetime Data Analysis 2007; 13:333-350.

Kim, M.Y.  Using the instrumental variables estimator to analyze non-inferiority trials with non-compliance.  Journal of Biopharmaceutical Statistics 2010; 20:745-758.

Heo, M., Kim, Y., Xue, X., Kim, M.  Sample size requirement to detect an intervention effect at the end of follow-up in a longitudinal cluster randomized trial.  Statistics in Medicine 2010; 29:382-290.

Xie, X., Xue, X., Gange, S., Strickler, H., Kim, M., and the WIHS HPV Study Group.  Estimationand inference on correlations between biomarkers with repeated measures and left-censoring dueto minimum detection levels. Statistics in Medicine 2012;  31:2275-2289

Wang, C., Hall, C., Kim, M. A comparison of power analysis methods for evaluating the effects of a predictor on slopes in longitudinal designs with missing data. Statistical Methods in Medical Research 2015; 24:1009-1029

Buyon, J., Kim, M., Guerra, M., Laskin, C., Petri, M., Lockshin, M., Sammaritano, L., Branch, W., Porter, F., Sawitzke, A., Merrill, J., Stephenson, M., Cohn, E., Garabet, L., Salmon, J.  Predictors of pregnancy outcome in a prospective multiethnic cohort of lupus patients. Annals of Internal Medicine 2015; 163:153-163

Kim, M., Wang, C., Xue, X. Assessing the influence of treatment non-adherence on non-inferiority trials using the tipping point approach. Statistics in Medicine 2019; 38:650-659

 

More Information About Dr. Mimi Kim

DEPH Faculty Page

Division of Biostatistics

Material in this section is provided by individual faculty members who are solely responsible for its accuracy and content.

Albert Einstein College of Medicine
Jack and Pearl Resnick Campus
1300 Morris Park Avenue
Belfer Building, Room 1303B
Bronx, NY 10461

Tel: 718.430.2017

Research Information